Author + information
- İlker Murat Caglar1,
- Cem Özde1,
- Fatma Nihan Turhan Çağlar2,
- Bülent Demir1,
- İsmail Ungan1,
- Faruk Aktürk3 and
- Osman Karakaya1
Slow coronary flow (SCF) is defined as delayed opacification of coronary arteries during coronary angiography without significant stenosis and is associated with myocardial perfusion abnormalities, myocardial ischemia and myocardial infarction. Although the certain etiology and pathophysiologic mechanism of SCF patients is still unknown, possible underlying mechanisms are endotelial dysfunction, chronic inflammation, microvascular dysfunction and diffuse atherosclerosis.
Lectin-like oxidized low density lipoprotein (LDL) receptor-1 (LOX-1); a receptor for oxidized-LDL; seems to play important roles in the pathogenesis of atherosclerotic plaque development and progression. LOX-1 is released as soluble forms (sLOX-1) after proteolytic cleavage that can be measured in serum.
The association between sLOX-1 and multiple stages of vascular dysfunction, including endothelial dysfunction, atherogenesis and launching/initiation of atherosclerotic plaque rupture have already been demonstrated by other studies. Our aim of this study was to evaluate the slOX-1 serum levels in patients with SCF phenomenon.
A total of 40 patients with angiographically proven coronary slow flow phenomenon (23 males and 17 females, mean age 56,33±13,04 years) and 43 patients with normal coronary arteries and normal coronary flow (16 males and 27 females, mean age 55,6±6,51 years) were included in this cross-sectional observational study. Coronary blood flow was measured according to the TIMI (Thrombolysis In Myocardial Infarction) frame count method for the all coronary arteries. sLOX-1 levels were measured in all study subjects from serum samples by sandwich enzyme-linked immunosorbent assay.
Serum levels of sLOX-1 were significantly higher in the SCF group than normal coronary artery group (1061,80±422,20ng/ml vs. 500,043±282,97 ng/ml, p<0.001, respectively). Also correlation analysis showed a positive correlation between serum sLOX-1 levels and the mean TIMI frame count (r<0.001).
The results of the present study show significantly higher sLOX-1 levels in patients with SCF compared to control subjects. The findings point out, sLOX-1 may be contributed in the pathogenesis of coronary slow flow.